Clinical Trials Logo

Filter by:
NCT ID: NCT05469139 Completed - Clinical trials for Extracorporeal Membrane Oxygenation Complication

Assessing Brain Injury Using Portable Magnetic Resonance Imaging (MRI)

SAFE MRI
Start date: December 10, 2021
Phase:
Study type: Observational

This study aims to assess the feasibility of assessing acute brain injury using a portable low field MRI in patients on ECMO.

NCT ID: NCT05469113 Completed - Healthy Clinical Trials

A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants

Start date: January 29, 2019
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to assess the effect of selpercatinib on how fast repaglinide gets into the blood stream and how long it takes the body to remove it when administered in healthy participants. Information about safety and tolerability will be collected. The study will last up to 12 days.

NCT ID: NCT05469100 Completed - Healthy Clinical Trials

A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function

Start date: December 19, 2018
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to assess the amount of study drug that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared to healthy participants. The study will last up to 9 days, excluding screening.

NCT ID: NCT05469048 Completed - Sepsis Clinical Trials

Near Patient Molecular Testing in Sepsis

NEPTUNE
Start date: March 12, 2020
Phase:
Study type: Observational

The purpose of the study is to evaluate the real-time performance of a new host response test (SeptiCyte RAPID) for differentiating sepsis from non-infection/systemic inflammatory response syndrome among patients suspected of sepsis within the first 24 hours of intensive care unit (ICU) admission.

NCT ID: NCT05468918 Completed - Hearing Loss Clinical Trials

Real World Perspectives on Advancements in Hearing Aid Technology

Start date: July 18, 2022
Phase: N/A
Study type: Interventional

This study will compare different microphone technologies in a noisy environment when the dominant speaker is at the front, back, left, or right side of the listener.

NCT ID: NCT05468749 Completed - Renal Impairment Clinical Trials

Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of CTP-543

Start date: June 6, 2022
Phase: Phase 1
Study type: Interventional

This is an open-label, single-dose, sequentially designed, single-period study to determine the effect of moderate renal impairment on the pharmacokinetics (PK) of CTP-543 and its major metabolites following administration of a single 12 mg oral dose of CTP-543.

NCT ID: NCT05468723 Completed - Infectious Diseases Clinical Trials

Evaluating Patient Comfort and Environmental Conditions in the Carecube Negative Pressure Isolation Chamber.1

Start date: May 24, 2022
Phase:
Study type: Observational

This is a human non-significant risk (NSR) clinical study designed to objectively and participatively verify that the Carecube Negative Pressure Isolation Chamber is a safe and non-hostile environment for the patients that will be contained within the chamber during normal operations.

NCT ID: NCT05468411 Completed - Diabetes Clinical Trials

Effects of Miracle Fruit Pill Application on Food Likings and Energy Intake in Diabetic or Prediabetic Patients

Start date: November 1, 2019
Phase: N/A
Study type: Interventional

The high prevalence of diabetes and prediabetes has increased the demand for nonnutritive sweeteners in recent years. Miracle fruit has been considered a healthy alternative sweetener for diabetic patients due to its sweetness-enhancing effects and high antioxidant activity. The purposes of this study are to examine whether the miracle fruit pill application to mouth prior to food consumption could improve the likings of different types of sour food (green apple, goat cheese, lemonade, cucumber pickle, and plain fat-free yogurt) and meals (breakfast, lunch, and dinner), and reduce energy intakes at the meals. Fifty volunteers (25 men and 25 women) aged 45 to 75 years with diabetes or prediabetes participate in the study. In this study, two interventions (miracle fruit and placebo) are provided, and all participants receive both applications. Participants are randomly assigned to one of the two interventions in part 1 and the assignment is switched from one application to another in part 2. The study hypotheses of this study are that the miracle fruit intervention improves the likings for sour foods and meals more than the placebo does; The miracle fruit intervention also reduces energy intakes from the meals more than the placebo does. Participants are asked to participate in a total of 6 sessions (1 hour/session, 1 session/day, Part 1: session 1, 2, & 3, Part 2: session 4, 5, & 6). Each session consists of two 30-min assessments, which are liking tests and meal intake assessment. The potential participants who have known food allergies or food intolerances are screened through consented screening procedure. If unknown food allergies or intolerances unintentionally become present during the study, medical help will be sought immediately. Participants may enjoy food samples and meals provided in this study and benefit by learning more about their acceptances for miracle fruit pill as an alternative sweetener. The results of this research are expected to develop generalizable knowledge about the miracle fruit's potential to improve the food palatability for people with diabetes or prediabetes.

NCT ID: NCT05468164 Completed - Healthy Clinical Trials

A Study of Effect of Food and a Proton Pump Inhibitor on Selpercatinib (LY3527723) in Healthy Participants

Start date: May 31, 2018
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to assess the effect of food on how fast selpercatinib gets into the bloodstream and how long it takes the body to remove it after a high-fat meal, and the effect of a change in gastric pH after multiple doses of omeprazole on how fast selpercatinib gets into the bloodstream and how long it takes the body to remove it when administered under fasted and fed conditions in healthy participants. The study will also evaluate the safety and tolerability of selpercatinib in healthy participants. The study will last up to 33 days excluding the screening period.

NCT ID: NCT05467982 Completed - Chronic Disease Clinical Trials

Brief COVID-19 Intervention for People With Serious Mental Illness and Co-Morbid Medical Conditions

Start date: October 1, 2020
Phase: N/A
Study type: Interventional

The study will enroll 600 people with serious mental illness who receive services at Centerstone in KY or TN and will compare two different evidence-based self-management interventions: Integrated Illness Management and Recovery (I-IMR), a program developed by the study team at Dartmouth that trains people with serious mental illness on physical and mental health self-management, and the Stanford Chronic Disease Self-Management Program (CDSMP), a program largely focused on physical health self-management that has been used widely in the general population. In addition, PCORI is funding an evaluation of a COVID-related intervention that will begin in the Fall 2020.